MetaCap

ALX Oncology (ALXO) vs Sionna Therapeutics (SION)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ALX Oncology (ALXO) has outperformed Sionna Therapeutics (SION) over the past year, losing 25.9% versus a loss of 93.5%. ALX Oncology is the larger company by market cap ($137.0 million vs $127.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALXO-25.87%SION-93.53%
+91%-6%-102%
Nov 21, 20251 yearNov 20, 2026
ALXO-2.75%SION-88.70%
+135%+18%-99%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALXO versus SION key metrics
MetricALXOSION
Share price$1.06$2.83
Market cap$137.03M$127.79M
1-day change+3.92%-4.88%
YTD return-6.19%-93.13%
1-year return-25.87%-93.53%
5-year return-96.84%—
EPS (TTM)$-0.87$-2.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-101.69M$-75.27M
52-week high$2.66$54.97
52-week low$0.862$2.75
Distance from 52-week high-60.15%-94.86%
Analyst consensusstrong_buyhold
Avg. price target upside+333.96%+643.36%
Average volume1.19M1.12M
Shares outstanding129.27M45.24M
Employees4959
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALXO has outperformed SION by 67.7 percentage points over the past year.

About ALX Oncology

ALXO stock →

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About Sionna Therapeutics

SION stock →

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees

ALXO vs SION FAQ

Which is bigger, ALX Oncology or Sionna Therapeutics?

ALX Oncology (ALXO) is larger, with a market capitalization of $137.03M compared with $127.79M for Sionna Therapeutics (SION).

Which stock has performed better over the past year, ALXO or SION?

ALXO returned -25.87% over the past 12 months, compared with -93.53% for SION (price return, excluding dividends). Past performance does not predict future results.

Are ALX Oncology and Sionna Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons